No Data
Jefferies Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $145
Glaukos IDose: Transforming Glaucoma Treatment With Promising Growth Potential
GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa
Glaukos Eyes FDA Approval for Ocular Therapy After Phase III Win
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $145
Stifel Nicolaus Issues a Buy Rating on Glaukos (GKOS)